Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Exploring the Potential Effects of Cryopreservation on the Biological Characteristics and Cardiomyogenic Differentiation of Rat Adipose-Derived Mesenchymal Stem Cells.

Farag A., Ngeun SK., Kaneda M., Aboubakr M., Elhaieg A., Hendawy H.

Animal Study on Cardiovascular Disease, Immune Modulation, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Mol Sci (2024)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
39337396
PMCID
PMC11432599
DOI
10.3390/ijms25189908
Citations
8

Abstract (original English)

Cryopreservation is essential for the broad clinical application of mesenchymal stem cells (MSCs), yet its impact on their cellular characteristics and cardiomyogenic differentiation potential remains a critical concern in translational medicine. This study aimed to evaluate the effects of cryopreservation on the biological properties and cardiomyogenic capacity of rat adipose-derived MSCs (AD-MSCs). We examined their cellular morphology, surface marker expression (CD29, CD90, CD45), trilineage differentiation potential (adipogenic, osteogenic, chondrogenic), and gene expression profiles for the pluripotency marker REX1 and immunomodulatory markers TGFβ1 and IL-6 . After inducing cardiomyocyte differentiation, we assessed cardiac-specific gene expressions ( Troponin I , MEF2c , GSK-3β ) using quantitative RT-qPCR, along with live/dead cell staining and immunofluorescence for cardiac-specific proteins (Troponin T, α-actinin, Myosin Heavy Chain). Cryopreserved AD-MSCs preserved their morphology, surface markers, and differentiation potential, but exhibited a reduced expression of REX1 , TGFβ1 , and IL-6 . Additionally, cryopreservation diminished cardiomyogenic differentiation, as indicated by the lower levels of Troponin I , MEF2c , and GSK-3β seen compared to non-cryopreserved cells. Despite this, high cell viability (>90%) and maintained cardiac protein expression were observe

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCryopreservationMesenchymal Stem CellsRatsCell DifferentiationMyocytes, CardiacAdipose TissueCell SurvivalCells, CulturedInterleukin-6

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research